Institutional Fund
Eversept Partners, LP
New York, NYCIK 16970135 filings on record
Portfolio Value
$1.52B
Q1 2026
Holdings
104
Reported positions
New Buys
32
Opened this quarter
QoQ Change
-14.9%
from $1.78B
Portfolio Value Trend
Reported 13F value by quarter
Portfolio value trend — upgrade to see history
UpgradeTop Allocations
Largest positions by weight
- United Therapeutics Corp Del10.3%
- Abivax SA6.9%
- Gsk PLC6.5%
- Vera Therapeutics Inc5.8%
- Natera Inc5.1%
- Syndax Pharmaceuticals Inc4.4%
- Other61.0%
Portfolio Holdings
104 positions · Q1 2026
| # | Security | Shares | Value | % Port. | Δ Shares | Activity |
|---|---|---|---|---|---|---|
| 1 | United Therapeutics Corp Del | 264.3K | $156.71M | 10.3% | +11.7K | Added |
| 2 | Abivax SA | 934.4K | $104.05M | 6.9% | +276.6K | Added |
| 3 | Gsk PLC | 1.79M | $98.52M | 6.5% | −894.5K | Reduced |
| 4 | Vera Therapeutics Inc | 2.17M | $87.43M | 5.8% | −899.0K | Reduced |
| 5 | Natera Inc | 384.7K | $76.94M | 5.1% | +50.2K | Added |
| 6 | Syndax Pharmaceuticals Inc | 2.89M | $67.41M | 4.4% | −428.8K | Reduced |
| 7 | Celldex Therapeutics Inc New | 1.79M | $56.72M | 3.7% | +353.3K | Added |
| 8 | Vaxcyte Inc | 924.2K | $53.70M | 3.5% | −273.5K | Reduced |
| 9 | Brookdale Sr Living Inc | 3.57M | $48.82M | 3.2% | +3.19M | Added |
| 10 | Ionis Pharmaceuticals Inc | 632.1K | $47.46M | 3.1% | +93.9K | Added |
94 more holdings on Premium
See this fund's complete portfolio, full position changes, and activity history.
Unlock full portfolio